IKZF1 and B-cell chronic lymphocytic leukemia: Although not a routine part of CLL clinical management, the immunomodulatory drug lenalidomide (a derivative of thalidomide that binds to cereblon and induces ubiquitination and the degradation of multiple targets such as IKZF1/Ikaros and IKZF3/Aiolos) has demonstrated activity in CLL, as well as significant stimulatory effects on natural killer cells (Figure 3) [242].